ZURNAI (AUTOINJECTOR) (nalmefene hydrochloride) by Purdue Pharma is clinical pharmacology pharmacodynamics nalmefene hydrochloride injection prevents or reverses the effects of opioids, including respiratory depression, sedation, and hypotension. First approved in 2024.
Drug data last refreshed 21h ago · AI intelligence enriched 1mo ago
ZURNAI is a nalmefene hydrochloride autoinjector designed for emergency reversal of opioid overdose and respiratory depression. It is an opioid antagonist with a longer duration of action than naloxone, offering rapid receptor occupancy (>80% of brain opioid receptors within 5 minutes). The drug has no agonist activity and does not produce respiratory depression, psychotomimetic effects, or abuse potential.
Recently approved product in growth phase; early-stage commercial team building with focus on emergency medicine and opioid crisis response market penetration.
CLINICAL PHARMACOLOGY Pharmacodynamics Nalmefene hydrochloride injection prevents or reverses the effects of opioids, including respiratory depression, sedation, and hypotension. Pharmacodynamic studies have shown that nalmefene hydrochloride injection has a longer duration of action than naloxone…
Worked on ZURNAI (AUTOINJECTOR) at Purdue Pharma? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Post-Marketing Surveillance Study of Nalmefene Hydrochloride Hydrate in Patients with Alcohol Dependence
Upgrade to Pro to access patent cliff timelines and LOE dates and other premium pharma intelligence.
Upgrade to Pro — $25/moZURNAI represents a growth-stage opportunity in the high-impact opioid crisis response market with 13+ years of patent protection. Pharma professionals joining this product now will build an emerging commercial franchise addressing critical public health needs with differentiated pharmacology.